Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Total Debt (2019)

Avidity Biosciences' Total Debt history spans 1 years, with the latest figure at $4.5 million for Q4 2019.

  • For Q4 2019, Total Debt changed N/A year-over-year to $4.5 million; the TTM value through Dec 2019 reached $4.5 million, changed N/A, while the annual FY2019 figure was $4.5 million, N/A changed from the prior year.
  • Total Debt reached $4.5 million in Q4 2019 per RNA's latest filing.
  • In the past five years, Total Debt ranged from a high of $4.5 million in Q4 2019 to a low of $4.5 million in Q4 2019.